NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.93 by $0.10. The medical equipment provider earned $204.97 million during the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a net margin of 26.92% and a return on equity of 19.89%. The firm's revenue was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 earnings per share. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for ABIOMED.

ABIOMED will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

ABIOMED issued an update on its third quarter 2020 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $221.6-221.6 million, compared to the consensus revenue estimate of $226.68 million.

7 Wall Street analysts have issued twelve-month price targets for ABIOMED's stock. Their forecasts range from $198.00 to $400.00. On average, they expect ABIOMED's share price to reach $294.50 in the next twelve months. This suggests a possible upside of 62.5% from the stock's current price. View Analyst Price Targets for ABIOMED.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

News stories about ABMD stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for ABIOMED.

ABIOMED saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,320,000 shares, an increase of 21.7% from the December 15th total of 3,550,000 shares. Based on an average daily trading volume, of 806,900 shares, the days-to-cover ratio is currently 5.4 days. Approximately 9.8% of the shares of the company are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Arista Networks (ANET), Square (SQ), Intuitive Surgical (ISRG), Netflix (NFLX), bluebird bio (BLUE) and Adobe (ADBE).

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Country Trust Bank (0.24%), Rhenman & Partners Asset Management AB (0.19%), Chicago Capital LLC (0.17%), Commerzbank Aktiengesellschaft FI (0.03%), State of Alaska Department of Revenue (0.02%) and Alpine Global Management LLC (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Country Trust Bank, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Alpine Global Management LLC, Commerzbank Aktiengesellschaft FI, Altman Advisors Inc., FNY Investment Advisers LLC, Kistler Tiffany Companies LLC, Nisa Investment Advisors LLC and Lenox Wealth Advisors LLC. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $181.28.

ABIOMED has a market capitalization of $8.19 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.

The official website for ABIOMED is http://www.abiomed.com/.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]med.com.